Chimeric double-stranded nucleic acid
A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.
1. A method of reducing the level of a transcription product in a cell comprising contacting the cell with a composition comprising:
a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein:
(i) the first nucleic acid strand is 8 to 100 nucleotides in length and hybridizes to the transcription product, comprises (a) a region consisting of at least 4 consecutive DNA nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, wherein the at least 4 consecutive DNA nucleotides may be modified or unmodified, and further comprises (b) one or more nucleotide analogs located on 5′ terminal side of the region, and (c) one or more nucleotide analogs located on 3′ terminal side of the region; and
(ii) the second nucleic acid strand (a) comprises at least 4 consecutive RNA nucleotides, and (b) further comprises a 5′ wing region of one or more modified nucleotides, nucleotide analogs and/or modified nucleotide analogs located 5′ to the at least 4 consecutive RNA nucleotides, and/or a 3′ wing region of one or more modified nucleotides, nucleotide analogs and/or modified nucleotide analogs located 3′ to the at least 4 consecutive RNA nucleotides, wherein the at least 4 consecutive RNA nucleotides can be cleaved by RNase H when the second nucleic acid strand is annealed with the first nucleic acid strand, and wherein the second nucleic acid strand further comprises a functional moiety having a function selected from a labeling function, a purification function, and a targeted delivery function.
2. The method according to claim 1 , wherein the total number of nucleotides and nucleotide analogs in the first nucleic acid strand and the total number of nucleotides and nucleotide analogs in the second nucleic acid strand are the same.
3. The method according to claim 1 , wherein the total number of nucleotides and nucleotide analogs in the first nucleic acid strand and the total number of nucleotides and nucleotide analogs in the second nucleic acid strand are different.
4. The method according to claim 1 , wherein the nucleotide analogs in the first nucleic acid strand are bridged nucleotides.
5. The method according to claim 1 , wherein at least one of the nucleotides and the nucleotide analogs in the first nucleic acid strand is phosphorothioated.
6. The method according to claim 1 , wherein the second nucleic acid strand comprises one or more phosphorothioated nucleotides located 5′ and/or 3′ to the at least 4 consecutive RNA nucleotides.
7. The method according to claim 1 , wherein the functional moiety is a molecule selected from a lipid, a glycolipid, a glyceride, a sugar, a peptide, and a protein.
8. The method according to claim 1 , wherein the functional moiety is a lipid selected from a group consisting of a fatty acid, a lipid-soluble vitamin, a glycolipid, and a glyceride.
9. The method according to claim 1 , wherein the functional moiety is a molecule selected from a group consisting of cholesterol, a tocopherol, a tocotrienol, glucose, sucrose, acylcarintine, acyl-CoA, and an antibody.
10. The method according to claim 1 , wherein at least one of the nucleotide analogs is a molecule selected from a group consisting of a hexitol nucleic acid (HNA), a cyclohexane nucleic acid (CeNA), a peptide nucleic acid (PNA), a glycol nucleic acid (GNA), a threose nucleic acid (TNA), a morpholino nucleic acid, a tricyclo-DNA (tcDNA), a 2′-O-methylated nucleic acid, a 2′-MOE (2′-O-methoxyethyl) lated nucleic acid, a 2′-AP (2′-O-aminopropyl) lated nucleic acid, a 2′-fluorinated nucleic acid, a 2′-F-arabinonucleic acid (2′-FANA), and a bridged nucleic acid (BNA).
11. The method according to claim 10 , wherein the BNA is a molecule selected from a group consisting of α-L-methyleneoxy (4′-CH 2 —O-2′) BNA, β-D-methyleneoxy (4′-CH 2 —O-2′) BNA, ethyleneoxy (4′-CH 2 -2-O-2′) BNA, β-D-thio (4′-CH 2 —S-2′) BNA, aminooxy (4′-CH 2 —O—N(R 3 )-2′) BNA, oxyamino (4′-CH 2 ′N(R 3 )—O-2′) BNA, 2′,4′-BNA-COC, 3′-amino-2′,4′-BNA, 5′-methyl BNA, 4′-CH(CH 3 )—O-2′-BNA, 4′-CH(CH 2 OCH 3 )—O-2′-BNA, amide (4′-C(O)—N(H)-2′) BNA, and amide (4′-C(O)—N(Me)-2′) BNA.